Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$39.53 USD
+0.04 (0.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $39.53 0.00 (0.00%) 4:44 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Mirum Pharmaceuticals, Inc. (MIRM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.09 | $71.00 | $39.00 | 44.57% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Mirum Pharmaceuticals, Inc. comes to $57.09. The forecasts range from a low of $39.00 to a high of $71.00. The average price target represents an increase of 44.57% from the last closing price of $39.49.
Analyst Price Targets (11)
Broker Rating
Mirum Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 11 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
6/18/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
6/17/2024 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
6/3/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
4/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/18/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 11 |
Average Target Price | $57.09 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.48 |